The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Amlodis     ethyl methyl2-(2- aminoethoxymethyl)-4-(2...

Synonyms: Amlocard, Amlopres, Coroval, Intervask, Lipinox, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Norvasc


Psychiatry related information on Norvasc


High impact information on Norvasc

  • In the patients who received amlodipine, treatment also lowered blood pressure but increased muscle sympathetic-nerve activity, from 41+/-19 to 56+/-14 bursts per minute (P=0.02) [11].
  • The possibility that amlodipine prolongs survival in patients with nonischemic dilated cardiomyopathy requires further study [1].
  • CONCLUSIONS: Despite comparable levels of ischemia, amlodipine attenuated stunning when compared with ISMN [12].
  • At rest, systemic and pulmonary vascular resistance (dyne . s-1 . cm-5) increased with CHF compared with the normal control state (3102+/-251 versus 2156+/-66 and 1066+/-140 versus 253+/-24, respectively, both P<0.05) and were reduced with amlodipine treatment (2108+/-199 and 480+/-74, respectively, P<0.05) [13].
  • BACKGROUND: This study examined the effects of chronic amlodipine treatment on left ventricular (LV) pump function, systemic hemodynamics, neurohormonal status, and regional blood flow distribution in an animal model of congestive heart failure (CHF) both at rest and with treadmill exercise [13].

Chemical compound and disease context of Norvasc


Biological context of Norvasc

  • Under ambient resting conditions, LV stroke volume (mL) was reduced with CHF compared with the normal control state (16+/-2 versus 31+/-2, P<0.05) and increased with concomitant amlodipine treatment (29+/-2, P<0.05) [13].
  • Thus, our study correlates an effect of amlodipine to lower intracellular calcium levels, by a mechanism not known at present, with its effect to inhibit HT-39 cell proliferation [15].
  • Insulin resistance decreased by using antihypertensive treatments with bunazosin, cilazapril, amlodipine, and benidipine in hypertensive subjects [18].
  • OBJECTIVES: The objective of this study was to test the predictive value of an oxidative stress biomarker in 634 patients from the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) [19].
  • Addition of the superoxide radical scavenger tempol restored the ability of bradykinin, enalaprilat, and amlodipine to suppress oxygen consumption in tissue from 23-mo-old animals to levels seen in younger animals, suggesting NO destruction by superoxide as the reason for decreased NO availability [20].

Anatomical context of Norvasc


Associations of Norvasc with other chemical compounds


Gene context of Norvasc


Analytical, diagnostic and therapeutic context of Norvasc


  1. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. Packer, M., O'Connor, C.M., Ghali, J.K., Pressler, M.L., Carson, P.E., Belkin, R.N., Miller, A.B., Neuberg, G.W., Frid, D., Wertheimer, J.H., Cropp, A.B., DeMets, D.L. N. Engl. J. Med. (1996) [Pubmed]
  2. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. Agodoa, L.Y., Appel, L., Bakris, G.L., Beck, G., Bourgoignie, J., Briggs, J.P., Charleston, J., Cheek, D., Cleveland, W., Douglas, J.G., Douglas, M., Dowie, D., Faulkner, M., Gabriel, A., Gassman, J., Greene, T., Hall, Y., Hebert, L., Hiremath, L., Jamerson, K., Johnson, C.J., Kopple, J., Kusek, J., Lash, J., Lea, J., Lewis, J.B., Lipkowitz, M., Massry, S., Middleton, J., Miller, E.R., Norris, K., O'Connor, D., Ojo, A., Phillips, R.A., Pogue, V., Rahman, M., Randall, O.S., Rostand, S., Schulman, G., Smith, W., Thornley-Brown, D., Tisher, C.C., Toto, R.D., Wright, J.T., Xu, S. JAMA (2001) [Pubmed]
  3. Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth. Ellis, J.S., Seymour, R.A., Thomason, J.M., Monkman, S.C., Idle, J.R. Lancet (1993) [Pubmed]
  4. Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial. Tzivoni, D., Kadr, H., Braat, S., Rutsch, W., Ramires, J.A., Kobrin, I. Circulation (1997) [Pubmed]
  5. Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. Weinberg, E.O., Lee, M.A., Weigner, M., Lindpaintner, K., Bishop, S.P., Benedict, C.R., Ho, K.K., Douglas, P.S., Chafizadeh, E., Lorell, B.H. Circulation (1997) [Pubmed]
  6. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. Miller, M., Byington, R., Hunninghake, D., Pitt, B., Furberg, C.D. Arch. Intern. Med. (2000) [Pubmed]
  7. Effects of Ca2+ antagonists on motor activity and the dopaminergic system in aged mice. Kurosaki, R., Akasaka, M., Michimata, M., Matsubara, M., Imai, Y., Araki, T. Neurobiol. Aging (2003) [Pubmed]
  8. Angiotensin II Receptor Blockers Downsize Adipocytes in Spontaneously Type 2 Diabetic Rats With Visceral Fat Obesity. Mori, Y., Itoh, Y., Tajima, N. Am. J. Hypertens. (2007) [Pubmed]
  9. Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient Compliance. Detry, J.M. Clinical cardiology. (1994) [Pubmed]
  10. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). Hobbs, F.D., Gensini, G., Mancini, G.B., Manolis, A.J., Bauer, B., Böhler, S., Genest, J., Feldman, R., Harvey, P., Jenssen, T.G., Metcalfe, M., da Silva, P.M. International journal of cardiology. (2006) [Pubmed]
  11. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. Ligtenberg, G., Blankestijn, P.J., Oey, P.L., Klein, I.H., Dijkhorst-Oei, L.T., Boomsma, F., Wieneke, G.H., van Huffelen, A.C., Koomans, H.A. N. Engl. J. Med. (1999) [Pubmed]
  12. Randomized, double-blind crossover study to investigate the effects of amlodipine and isosorbide mononitrate on the time course and severity of exercise-induced myocardial stunning. Rinaldi, C.A., Linka, A.Z., Masani, N.D., Avery, P.G., Jones, E., Saunders, H., Hall, R.J. Circulation (1998) [Pubmed]
  13. Chronic amlodipine treatment during the development of heart failure. Spinale, F.G., Mukherjee, R., Krombach, R.S., Clair, M.J., Hendrick, J.W., Houck, W.V., Hebbar, L., Kribbs, S.B., Zellner, J.L., Dodd, M.G. Circulation (1998) [Pubmed]
  14. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. Wang, W.Z., Matsumori, A., Yamada, T., Shioi, T., Okada, I., Matsui, S., Sato, Y., Suzuki, H., Shiota, K., Sasayama, S. Circulation (1997) [Pubmed]
  15. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Taylor, J.M., Simpson, R.U. Cancer Res. (1992) [Pubmed]
  16. Calcium channel blockers and mortality in elderly patients with myocardial infarction. Jollis, J.G., Simpson, R.J., Chowdhury, M.K., Cascio, W.E., Crouse, J.R., Massing, M.W., Smith, S.C. Arch. Intern. Med. (1999) [Pubmed]
  17. Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril. Jugdutt, B.I., Menon, V., Kumar, D., Idikio, H. J. Am. Coll. Cardiol. (2002) [Pubmed]
  18. Mechanism and clinical implication of insulin resistance syndrome. Suzuki, M., Ikebuchi, M., Shinozaki, K., Hara, Y., Tsushima, M., Matsuyama, T., Harano, Y. Diabetes (1996) [Pubmed]
  19. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. Walter, M.F., Jacob, R.F., Jeffers, B., Ghadanfar, M.M., Preston, G.M., Buch, J., Mason, R.P. J. Am. Coll. Cardiol. (2004) [Pubmed]
  20. Oxidant stress leads to impaired regulation of renal cortical oxygen consumption by nitric oxide in the aging kidney. Adler, S., Huang, H., Wolin, M.S., Kaminski, P.M. J. Am. Soc. Nephrol. (2004) [Pubmed]
  21. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). Deanfield, J.E., Detry, J.M., Lichtlen, P.R., Magnani, B., Sellier, P., Thaulow, E. J. Am. Coll. Cardiol. (1994) [Pubmed]
  22. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. Yasunari, K., Maeda, K., Watanabe, T., Nakamura, M., Yoshikawa, J., Asada, A. J. Am. Coll. Cardiol. (2004) [Pubmed]
  23. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. Chen, L., Haught, W.H., Yang, B., Saldeen, T.G., Parathasarathy, S., Mehta, J.L. J. Am. Coll. Cardiol. (1997) [Pubmed]
  24. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. Iñigo, P., Campistol, J.M., Lario, S., Piera, C., Campos, B., Bescós, M., Oppenheimer, F., Rivera, F. J. Am. Soc. Nephrol. (2001) [Pubmed]
  25. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). Jørgensen, B., Simonsen, S., Endresen, K., Forfang, K., Vatne, K., Hansen, J., Webb, J., Buller, C., Goulet, G., Erikssen, J., Thaulow, E. J. Am. Coll. Cardiol. (2000) [Pubmed]
  26. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Whelton, P.K., Barzilay, J., Cushman, W.C., Davis, B.R., Iiamathi, E., Kostis, J.B., Leenen, F.H., Louis, G.T., Margolis, K.L., Mathis, D.E., Moloo, J., Nwachuku, C., Panebianco, D., Parish, D.C., Pressel, S., Simmons, D.L., Thadani, U. Arch. Intern. Med. (2005) [Pubmed]
  27. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. Takebayashi, K., Matsumoto, S., Aso, Y., Inukai, T. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  28. Role of L-type calcium channel blocking in epidermal growth factor receptor-independent activation of extracellular signal regulated kinase 1/2. Yin, X., Polidano, E., Faverdin, C., Marche, P. J. Hypertens. (2005) [Pubmed]
  29. Calcium [corrected] channel blockers reduce angiotensin II-induced superoxide generation and inhibit lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells. Toba, H., Shimizu, T., Miki, S., Inoue, R., Yoshimura, A., Tsukamoto, R., Sawai, N., Kobara, M., Nakata, T. Hypertens. Res. (2006) [Pubmed]
  30. Different effects of amlodipine and enalapril on the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase pathway for induction of vascular smooth muscle cell differentiation in vivo. Umemoto, S., Kawahara, S., Hashimoto, R., Umeji, K., Matsuda, S., Tanaka, M., Kubo, M., Matsuzaki, M. Hypertens. Res. (2006) [Pubmed]
  31. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Yoshii, T., Iwai, M., Li, Z., Chen, R., Ide, A., Fukunaga, S., Oshita, A., Mogi, M., Higaki, J., Horiuchi, M. Hypertens. Res. (2006) [Pubmed]
WikiGenes - Universities